

## de cardiologie

Communauté. Connaissances. Leadership.

## **Disclosure of Potential Conflict of Interest**

The Canadian Cardiovascular Society (CCS) strives to enrich the sharing of best practices through the delivery of unbiased research findings. To this end, the CCS is committed to ensuring balance, independence, objectivity, and scientific rigor in the presentation of research, publications and educational activities within all co-developed programs.

A Conflict of Interest may occur in situations where personal and professional interest of individuals may have actual, potential or apparent influence over their judgment.

All financial or 'in kind' relationships (not only those relevant to the subject being discussed) encompassing the previous two (2) years must be disclosed.

The intent of this policy is not to prohibit information from being shared, but rather to inform the audience of any possible bias on the part of the author(s). It is the author's responsibility to ensure that content is balanced and reflects the current scientific literature. Unapproved use of products or services must be declared. The only caveat to this guideline is where there is only one treatment or management strategy.

In addition to completing this form, disclosures must be done verbally, displayed in writing on a slide at the beginning of a presentation or included in written materials.

Note: It is the responsibility of the primary author to collect and complete disclosure information for secondary authors.

Completed forms will be kept at the CCS office for 3 years following publication of the document.

Conflict of Interest Disclosures can be included in published manuscripts and /or posted to the CCS website.

## **Disclosure of Potential Conflict of Interest Form**

To return the completed form, please save it as an attachment and email to cpd@ccs.ca

All presenters and planning committee members must complete this form and submit to the CCS.

First N	lame:		Las	st Name					
Email:									
Title of Educational Program:		Innovating, Optimizing, and Advancing Antithrombotic Treatment in Atrial Fibrillation							
Date of Program:				cation of ogram:					
File Number		2016-37	Sp	onsor	BMS Pfizer Alliance				
Please	Please check one:								
	I do not have an affiliation (financial or otherwise) with a commercial organization within the previous two (2) years that may have a direct or indirect connection to the content of this presentation.								
	I have/had an affiliation (financial or otherwise) with a commercial organization within the previous two (2) years that may have a direct or indirect connection to the content of this manuscript. If you check this one, please provide details in the next question.								
Relevant Disclosure Relationships									
<b>Consulting Fees/Honoraria</b> : Including honoraria from a third party, gifts or other consideration, or "in kind" compensation, whether for consulting, lecturing, travel, service on an advisory board, legal testimony or consultation or for any other similar purpose in the prior two calendar years.									
None									
	Abbott Vascular			Amgen					
	AstraZeneca			Bayer					
	Boehringer Ingelheir	m [		Boston Scien	tific				
	BMS/Pfizer Alliance			Bristol-Myer	s Squibb				
	Edwards Lifescience	s [		Eli Lilly					
	GlaxoSmithKline			Johnson & Jo	hnson				
	Medtronic			Merck					
	Novartis			Otsuka					
	Pfizer			Roche					
	Sanofi			Schering Plo	ugh				
	Servier			St. Jude Med	lical				
	Other, please specify	y							

<b>Clinical Trials</b> : Participating in a clinical trial sponsored by a commercial organization that may have a direct or indirect connection to the content of my presentation.						
r	None					
	Abbott Vascular		Amgen			
	AstraZeneca		Bayer			
	Boehringer Ingelheim		Boston Scientific			
	BMS/Pfizer Alliance		Bristol-Myers Squibb			
	Edwards Lifesciences		Eli Lilly			
	GlaxoSmithKline		Johnson & Johnson			
	Medtronic		Merck			
	Novartis		Otsuka			
	Pfizer		Roche			
	Sanofi		Schering Plough			
	Servier		St. Jude Medical			
	Other, please specify					
Officer, Director, or in Any Other Fiduciary Role: Whether or not remuneration is received for service.  None Yes, please specify the company/organization  Ownership/Partnership/Principal: Excluding mutual diversified funds None Yes, please specify the company/organization  Intellectual Property Rights: Includes patent or other intellectual property in a for-profit corporation None Yes, please specify the company/organization						
Other Financial Benefit None Yes, please specify the company/organization  I acknowledge that the above information is accurate and that the content developed/presented is valid, objective, balanced and clinically relevant for physicians  Yes No						
Date	Signature					